Defining Exacerbation Could Produce Endpoint For Non-Cystic Fibrosis Bronchiectasis, FDA Told
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency received input on the natural history of the disease and options for measuring exacerbation to assess therapeutic success during a Sept. 7 workshop.
You may also be interested in...
Trial Designs For Non-Cystic Fibrosis Bronchiectasis May Need Refinement
FDA public workshop will consider the design of clinical studies testing antibacterial drugs to treat lung damage caused by recurrent infections.
Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.
Track-And-Trace: With Deadline a Year Away, Some Lessons from Early Adopters
EMD Serono has been tracking Serostim packages since 2002; J&J is using Prezista 600 mg as a trial run for serialization.